Management of dyskinesia in Parkinson's disease

7 July 2020, 1:44 EDT

Share:

Most Popular

Serum uric acid levels in patients with myasthenia gravis are inversely correlated with disability

Identifying Predictors of Acute Respiratory Failure in Myasthenia Gravis Using Machine Learning

Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies

Poll of the Week

What is the approximate 7-day risk for stroke after transient ischemic attack (TIA)?

A. 0.05%

B. 1%

C. 5%

D. 20%

Articles
Multimedia
Blog
Resources

About FocusOn
Privacy Policy
Terms of Use

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our Privacy and Cookie Policy.

|

Cookie Policy

Information about our use of cookies

Wolters Kluwer ("we" or "us") wants to inform you about the ways we process your personal information. In this Privacy & Cookie Notice we explain what personal information we collect, use and disclose.

Personal information means any data relating to an individual who can be identified, directly or indirectly, based on that information. This may include information such as names, contact details, (online) identification data, online identifiers, or other characteristics specific to that individual.